Publications
2026
HRDPath: an explainable multi-model deep learning architecture for predicting homologous recombination deficiency from histopathology images. DOI: 10.1038/s41467-026-78430-y
Cervical Cancer Screening With Human Papillomavirus Self-Collection Testing in an Opioid Treatment Program. DOI: 10.1001/jamanetworkopen.2026.25993
Patient-Centered Approach to Surgical Prevention of Ovarian Cancer: A Nonrandomized Clinical Trial. DOI: 10.1001/jamanetworkopen.2026.22026
International trends in concurrent hysterectomy at risk-reducing surgery in BRCA1/2 pathogenic variant carriers: a mixed-methods study. DOI: 10.1016/j.ajog.2026.06.017
HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications. DOI: 10.1158/1078-0432.CCR-25-1629
Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype. DOI: 10.1182/blood.2025031996
Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer. DOI: 10.1200/PO-25-00763
Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis. DOI: 10.1200/oa-25-00142
Cancer genetic testing uptake in the primary care setting: Patient perspectives on barriers and facilitators throughout the testing process. DOI: 10.1002/jgc4.70195
Patient-reported actions following receipt of pathogenic hereditary cancer genetic test results: results from a population-based screening study in primary care. DOI: 10.1186/s12875-026-03178-9
2025
Tissue Bank:
TP53 somatic evolution in the normal endometrium of Black and White individuals. DOI: 10.1016/j.ygyno.2025.04.002
Dynamic Monitoring of Recurrent Ovarian Cancer Using Serial ctDNA: A Real-World Case Series. DOI: 10.3390/curroncol32100585
Clinical Trials:
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial. DOI: 10.1016/j.ejca.2025.115584
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results. DOI: 10.1016/j.ejca.2025.115587
Strategies to Assess Risk for Hereditary Cancer in Primary Care Clinics: A Cluster Randomized Clinical Trial. DOI: 10.1001/jamanetworkopen.2025.0185
Primary care provider practices, attitudes, and confidence with hereditary cancer risk assessment and testing: A mixed methods study. DOI: 10.1016/j.gim.2024.101307
Advancing equity in cancer research through principled partnership: stakeholder engagement practices in The Social Interventions for Support during Treatment for Endometrial cancer and Recurrence (SISTER) Study. DOI: 10.1186/s40900-025-00760-w
Other:
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer. DOI: 10.1016/j.ccell.2025.07.005
Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functions. DOI: 10.1038/s41467-025-61283-2
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity. DOI: 10.1186/s40164-025-00681-0
Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance. DOI: 10.1093/nar/gkaf990
Cost-effectiveness of primary care-based risk assessment and hereditary cancer genetic testing. DOI: 10.1186/s12875-025-03137-w
Salpingectomy in individuals at high risk for tubo-ovarian cancer: consensus and precaution. DOI: 10.1016/j.ajog.2025.10.044
Impact of Global Enrollment on Race, Ethnicity, and Age Representation in Pivotal Gynecologic Cancer Trials Leading to US Food and Drug Administration Drug Approvals. DOI: 10.1200/GO-24-00636
Impact of breast cancer history on decision-making for ovarian cancer risk-reducing surgery in the TUBA-WISP-II study. DOI: 10.1016/j.ajog.2025.06.024
Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access. DOI: 10.1093/jnci/djae338
Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models. DOI: 10.1002/ctm2.70274
Diverse Patterns of Allele-Specific Expression in Healthy Human Tissues. DOI: 10.1101/2025.10.14.682127
DNA repair and the contribution to chemotherapy resistance. DOI: 10.1186/s13073-025-01488-8
2024
Tissue Bank:
Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations. DOI: 10.1016/j.ygyno.2024.07.690
TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations. DOI: 10.1038/s41388-024-03089-y
Identification of fallopian tube microbiota and its association with ovarian cancer. DOI: 10.7554/eLife.89830
CHANCES: No Publications for this study yet
Clinical Trials:
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib. DOI: 10.1016/j.ygyno.2024.05.002
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial. DOI: 10.1038/s41467-024-47215-6
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. DOI: 10.1038/s41416-023-02534-1
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. DOI: 10.1002/cncr.35151
Primary care provider practices, attitudes, and confidence with hereditary cancer risk assessment and testing: A mixed methods study. DOI: 10.1016/j.gim.2024.101307
Other:
R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription Replication Conflicts. DOI: 10.1158/0008-5472.CAN-23-3239
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance. DOI: 10.1186/s12943-024-02048-1
Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer. DOI: 10.6004/jnccn.2023.7331
Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors. DOI: 10.1186/s12943-024-02125-5
The role of aberrant DNA methylation in cancer initiation and clinical impacts. DOI: 10.1177/17588359231220511
More Publications
Dr. Swisher’s bibliography can be found on MyNCBI.